- Home
- PETS vs SRTS Comparison
PETS vs SRTS Comparison
Compare PETS & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | SRTS |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 67.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PETS | SRTS |
|---|---|---|
| Price | $3.29 | $4.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.20 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 7.7M | 72.4K |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $198,265,000.00 | $35,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | $29.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $3.03 |
| 52 Week High | $5.58 | $9.08 |
Technical Indicators
Market Signals| Indicator | PETS | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 61.35 |
| Support Level | $3.13 | $3.65 |
| Resistance Level | $3.64 | $3.92 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 39.55 | 93.85 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.